NCT06710756 2026-01-16Lead-212 PSV359 Therapy for Patients With Solid TumorsPerspective TherapeuticsPhase 1/2 Recruiting112 enrolled
NCT05275478 2025-11-14Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid TumorsTango Therapeutics, Inc.Phase 1/2 Active not recruiting192 enrolled
NCT05732831 2025-11-14Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsTango Therapeutics, Inc.Phase 1/2 Recruiting225 enrolled
NCT02611024 2025-07-09Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid TumorsPharmaMarPhase 1/2 Completed316 enrolled
NCT02859415 2022-04-05Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary MetastasesNational Institutes of Health Clinical Center (CC)Phase 1/2 Terminated3 enrolled 10 charts
NCT03638206 2019-12-11Autologous CAR-T/TCR-T Cell Immunotherapy for MalignanciesShenzhen BinDeBio Ltd.Phase 1/2 Unknown73 enrolled